Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
46.92%
Operating Margin
31.17%
Net Margin
21.95%
Efficiency Metrics
Revenue per Expense Ratio
1.45
R&D as % of Revenue
0.11%
Earnings Quality
EBITDA Margin
34.74%
Income Tax Rate
29.80%
EPS
3.8500000000
Balance Sheet Analysis
Current Ratio
2.27
Cash Ratio
0.56
Working Capital
$299.87M
Debt to Equity
0.31
Debt to Assets
17.66%
Equity Ratio
56.92%
Cash Flow Analysis
Operating Cash Flow Ratio
16.93%
Free Cash Flow Ratio
7.58%
CapEx to Revenue
9.36%
Dividends Paid
$16.43M
Stock Buybacks
$23.54M
Total Shareholder Returns
$39.96M
Cash Position Change
24.92%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 28.09%
Increased R&D investment by 50.00%
Detailed Growth Metrics
Core Performance
Revenue
16.29%
Net Income
17.43%
EPS
17.74%
Operating Income
14.73%
Operational Efficiency
R&D Expenses
50.00%
SG&A Expenses
-1.00%
Operating Cash Flow
-2.18%
Free Cash Flow
-13.78%
Balance Sheet Health
Assets
31.11%
Debt
0.31%
Book Value per Share
56.98%
Inventory
27.26%
Shareholder Returns
Dividends per Share
28.09%
Shares Outstanding
-0.35%
Long Term Trends
3Y Revenue/Share
117.05%
5Y Revenue/Share
77.35%
3Y Dividend/Share
322.07%
5Y Dividend/Share
377.90%